HeartBeam closed Monday up roughly 50% after the FDA granted a Breakthrough Device Designation, Socket Mobile ripped 31.6% on 77.5 million shares for the second straight session, and a tiny Israeli quantum-interconnect name pushed past $1. That is the backdrop for the penny stocks to watch on Tuesday, October 6. All ten trade under $2, and most are micro caps with real catalysts, real dilution risk, or both. If you want the full setup for each, the levels below are built from verified closes, intraday ranges, 52-week extremes and analyst targets.
Penny Stocks to Watch Tomorrow: Monday’s Market Snapshot
| Metric | Monday Close / Reading |
|---|---|
| S&P 500 | 7,773.95 (+0.66%) |
| Nasdaq Composite | 27,477.31 (+1.05%), record close |
| Dow Jones Industrial Average | 51,267.90 (+0.18%) |
| Russell 2000 | 2,853.27 (+0.72%) |
| 10-Year Treasury Yield | ~5.31%, a new 52-week high |
| Oil | WTI near $90 |
| Macro Backdrop | Fed hiked in September; September payrolls added just 29,000 jobs |
The Nasdaq finished at a record as tech led the tape, but the 10-year yield hit a fresh 52-week high, which usually squeezes unprofitable small caps. Fed minutes land Wednesday.
Data note: Closes are Monday, October 5 figures where an authoritative source was available. Where feeds disagreed or no single close was published, we say “near,” “roughly” or “not confirmed.” Support and resistance levels are analytical zones, not guaranteed targets. Penny stocks are highly speculative; a recent AltIndex screen of ten popular penny names showed an average six-month return of -42.7%, with just one of ten positive.
1. HeartBeam (BEAT) | Last Close ~$0.65 (+50.5%) | FDA Breakthrough Pop
From $0.43 to Heart-Attack Headlines: The Breakthrough Designation Gap Trade
HeartBeam said the FDA granted Breakthrough Device Designation for its at-home heart attack assessment tool, and shares spiked as much as 90% intraday before settling lower.
| Metric | Value |
|---|---|
| Last Close | ~$0.65 (after-hours ~$0.68) |
| Previous Close | $0.43 (Friday, Oct 2) |
| Day’s Move | +50.5% (intraday high near +90%; midday ~$0.71) |
| 52-Week Range | Low $0.36 (Sep 24); high above $1.30 (traded ~$1.33 in Feb) |
| Market Cap | $38.15M (vs. $24.49M Friday) |
| P/E / Dividend | N/A (pre-revenue on this program) / None |
| Volume vs. Average | Oct 5 total not confirmed; 61-day average ~625K |
| YTD / Trend | Down sharply from early-2026 levels near $1.30 |
| Analyst View | Thin coverage; no consensus located |
| Support 1 / 2 / 3 | $0.55 / $0.43 / $0.36 |
| Resistance 1 / 2 / 3 | ~$0.72 / ~$0.83 / ~$0.94–$0.99 |
Catalyst & Latest News: Benzinga reports the FDA responded within 30 days of the request, and the designation can open expedited Medicare pathways. A 134-patient pilot comes before a pivotal study.
Technicals: Friday’s $0.43 close sat in a tight $0.36–$0.45 September base. Monday’s gap cleared it, and $0.94–$0.99 was the May 2026 resistance zone.
Fundamentals: The heart-attack program rides the same 3D ECG platform as its FDA-cleared arrhythmia product, so no new hardware is expected. The company estimates the heart-attack market near $15 billion. It still has minimal revenue and recurring losses.
Bull Case: Regulatory validation, a large addressable market and a small float can attract follow-through buyers. Bear Case: Designation is not clearance, a pivotal trial is still ahead, and micro caps often raise capital after spikes.
What to Watch:
- Whether $0.55 holds on a pullback
- Any financing announcement
- Pivotal-study design news
Forecast: Holding $0.55 keeps $0.72 and $0.83 in play. A close back under $0.43 erases the gap.
Why This Matters: BEAT is the cleanest regulatory-catalyst story on the list, and also the one most exposed to a post-pop offering.
2. Socket Mobile (SCKT) | Last Close $0.93 (+31.6%) | 77.5 Million Shares Traded
The Barcode Scanner Maker That Turned Into a 72% Two-Day Sprint
Socket Mobile gained about 31% on Friday and 31.6% on Monday, taking it from $0.54 to $0.93 in two sessions. Google Finance shows volume of 77.54 million against an 8.15 million average.
| Metric | Value |
|---|---|
| Last Close | $0.93 (after-hours $0.92) |
| Previous Close | $0.71 (Friday, Oct 2: $0.7073) |
| Day’s Move | +31.6% (Friday: +31.0%) |
| Day’s Range | $0.76 – $1.19 |
| 52-Week Range | $0.38 – $2.76 |
| Market Cap | ~$7.7M |
| P/E / Dividend | N/A (EPS -$1.85) / None |
| Volume vs. Average | 77.54M vs. 8.15M (~9.5x) |
| YTD / Trend | Roughly +100% YTD (est.); -47% over 12 months before the spike |
| Analyst View | No active Wall Street coverage located |
| Support 1 / 2 / 3 | $0.85 / $0.71 / $0.54 |
| Resistance 1 / 2 / 3 | $1.00 / $1.19 / $2.76 |
Catalyst & Latest News: We found no company-specific news for Monday’s move. Recent headlines include an Orda collaboration on August 24 and a Nasdaq noncompliance listing notice on August 28.
Technicals: StockAnalysis data shows a 50-day average near $0.64 and a 200-day near $0.85. The stock now sits above both, with an intraday reversal from $1.19 to $0.93 showing sellers at the highs.
Fundamentals: Cash was $1.6 million at June 30, with total equity of $2.4 million. Float is only 5.74 million shares and insiders own about 31%.
Bull Case: An ultra-low float, reclaimed moving averages and an August precedent (a +451.7% day on August 10) keep momentum traders engaged. Bear Case: Thin cash, a listing notice, no identified catalyst and a 20% pullback from the high.
What to Watch:
- A hold above the $0.85 200-day area
- Earnings, estimated for October 21 after the close
- Any equity raise or compliance update
Forecast: A reclaim of $1.00 targets $1.19. Losing $0.71 opens $0.54.
Why This Matters: SCKT shows how fast a sub-$10 million float can move without news, in both directions.
3. PDS Biotechnology (PDSB) | Last Close $1.07 (+42.3%) | Up 325% in a Month
The Oncology Name With a Soon-Shiong Backstop and a Vertical Chart
Morningstar shows PDSB at $1.07, up $0.32 from a $0.75 prior close, on 24 million shares versus a 21 million average.
| Metric | Value |
|---|---|
| Last Close | $1.07 (intraday high near $1.18) |
| Previous Close | $0.75 (Friday, Oct 2) |
| Day’s Move | +42.3% |
| 52-Week Range | $0.20 – $1.54 |
| Market Cap | ~$74.7M |
| P/E / Dividend | N/A (2026 EPS estimate -$0.49) / None |
| Volume vs. Average | 24M vs. 21M |
| YTD / Trend | Roughly +10–15% YTD (est.); ~+325% in the past month |
| Analyst View | Strong Buy, 3 analysts; average target $4.75 ($4.50–$5.00); MarketBeat consensus Hold |
| Support 1 / 2 / 3 | $0.78 / $0.75 / ~$0.28 |
| Resistance 1 / 2 / 3 | ~$1.18 / $1.54 / $2.00 |
Catalyst & Latest News: We could not pin a single trigger for Monday. Background: the company refocused on PDS0301 in metastatic colorectal cancer, and an initial closing of up to $22.3 million in PIPE financing brought Dr. Patrick Soon-Shiong onto the board. The stock’s biggest daily gain this year was +69.2% on September 16.
Technicals: The stock went from near $0.28 in early September to above $1. The prior-session low of $0.75 is the key gap level.
Fundamentals: Clinical-stage, no product revenue. Shares outstanding were about 72 million in Morningstar’s data.
Bull Case: Fresh financing, a new focus and analyst targets near $4.75 leave room for re-rating. Bear Case: A 4x run in a month, dilution risk, and a Weiss “sell” rating.
What to Watch:
- A hold above $0.78
- Another test of $1.18
- PDS0301 clinical updates
Forecast: Closing above $1.18 targets $1.54. A fade under $0.75 erases most of Monday.
Why This Matters: Biotech penny names can reprice fast, and PDSB is now an extended chart that needs follow-through to avoid a round trip. See how a similar catalyst played out in our Capricor Therapeutics forecast.
4. QTREX Quantum (QTEX) | Last Close $1.29 (+17.3%) | Quantum Interconnect Breakout
Friday’s 40% Surge Gets a Monday Encore, With a Binding Deal “Within Weeks”
Formerly Inspira Technologies, QTEX closed Friday at $1.10 after a 40.2% surge and tacked on another 17% Monday.
| Metric | Value |
|---|---|
| Last Close | $1.29 (per Benzinga’s Oct 5 board) |
| Previous Close | $1.10 (Friday, Oct 2) |
| Day’s Move | +17.3% (Friday: +40.2%) |
| Day’s Range | ~$1.22 – $1.45 (premarket reportedly higher) |
| 52-Week Range | Not confirmed; September base was $0.68–$0.90 |
| Market Cap | ~$83M–$90M (feeds vary) |
| P/E / Dividend | N/A (about -3x) / None |
| Volume vs. Average | Benzinga average ~4.8M; Robinhood lists ~16M; feeds conflict |
| YTD / Trend | +34.7% in the month through Friday, more after Monday |
| Analyst View | TipRanks Spark: Neutral; no Wall Street targets located |
| Support 1 / 2 / 3 | $1.22 / $1.10 / $0.90 |
| Resistance 1 / 2 / 3 | $1.45 / $1.68 / $2.00 |
Catalyst & Latest News: Independent tests showed more than 100 dB of channel isolation at 20 millikelvin, with no crosstalk detected. Investors are waiting on a binding commercial deal with an unnamed quantum company, expected within weeks.
Technicals: QTEX moved from a $0.75–$0.90 range to above $1 in two sessions, and intraday swings of $0.40 or more are normal.
Fundamentals: Cash is roughly $3.2 million with working capital near $1.6 million, which leaves little cushion. The company plans to divest a legacy medical-device line, and the CEO has bought shares under a purchase plan.
Bull Case: A signed deal could validate the technology and quantum sentiment is hot. Bear Case: If the deal slips or disappoints, a thin balance sheet makes an equity raise likely.
What to Watch:
- The deal announcement
- A hold above $1.10
- Offering or ATM language in filings
Forecast: A confirmed deal could retest $1.45–$1.68. Losing $1.10 points to $0.90.
Why This Matters: QTEX is the purest “headline-or-bust” quantum play in the group.
5. Humacyte (HUMA) | Last Close Near $0.50 (~-4%) | Fresh 52-Week Low Zone
A $144 Million Bioengineered-Vessel Maker Trading Like It’s Out of Cash
Humacyte sits at the bottom of its range, with a $2.55 52-week high and a low near $0.50 per Robinhood.
| Metric | Value |
|---|---|
| Last Close | Near $0.50 (not confirmed to the cent) |
| Previous Close | ~$0.52 (Friday, Oct 2) |
| Day’s Move | Roughly -4% |
| Day’s Range | Friday: $0.50 – $0.53 |
| 52-Week Range | $0.50 – $2.55 |
| Market Cap | ~$144.5M |
| P/E / Dividend | -1.07 / None |
| Volume vs. Average | Friday 5.4M vs. 3.85M average |
| YTD / Trend | Down ~80% from the 52-week high |
| Analyst View | Buy, 5 analysts; average target $1.85 (+270%) |
| Support 1 / 2 / 3 | $0.50 / $0.45 / $0.40 |
| Resistance 1 / 2 / 3 | $0.53 / $0.64 / $1.00 |
Catalyst & Latest News: A supplemental BLA for dialysis access is planned for November 2026, and CABG trials start this year. The FDA also extended Symvess shelf life from 18 to 36 months.
Technicals: Lower highs since the Q2 report, when shares fell about 10% premarket to $0.636. A break of $0.50 means price discovery with no support.
Fundamentals: Q1 Symvess sales were just $0.5 million (29 units). Q2 missed badly: revenue came in about 63% short and EPS about 78% below estimates. A 2026 cost-savings target of $14.3 million is in place.
Bull Case: An approved product, a dialysis filing and a $1.85 target with a stock below $1. Bear Case: Tiny sales, repeated misses, fundraising risk, and a sub-$1 price that invites a Nasdaq bid-price deficiency if it persists.
What to Watch:
- $0.50 as support
- Dialysis sBLA timing
- Q3 results, expected in early November
Forecast: A close above $0.64 begins a recovery. Under $0.50, $0.45 and $0.40 are the next markers.
Why This Matters: HUMA is the “approved but not selling” case study for commercial-stage biotech.
6. Rapid Micro Biosystems (RPID) | Last Close ~$1.07 (+16.8%) | Rebound From the Lows
The Automation Play Bouncing Off a $0.86 Floor With a $5 Average Target
RPID closed Friday at $0.92 with a market cap near $41.7 million and a 52-week range of $0.86 to $4.94. Benzinga’s Oct 5 mover board shows it up 16.8% near $1.07.
| Metric | Value |
|---|---|
| Last Close | ~$1.07 (per Benzinga board) |
| Previous Close | $0.92 (Friday, Oct 2) |
| Day’s Move | +16.8% |
| Day’s Range | Not confirmed |
| 52-Week Range | $0.86 – $4.94 |
| Market Cap | ~$42M Friday (roughly $48M+ at Monday’s price) |
| P/E / Dividend | N/A (loss-making) / None |
| Volume vs. Average | Friday 329K; average ~265K per Benzinga |
| YTD / Trend | Down ~78% from the 52-week high |
| Analyst View | Strong Buy skew; average target about $5.00 |
| Support 1 / 2 / 3 | $0.92 / $0.86 / $0.75 |
| Resistance 1 / 2 / 3 | $1.10 / ~$1.31 / $2.00 |
Catalyst & Latest News: No headline explained Monday’s pop. Q2 revenue was $8.05 million (+11%) versus a $7.88 million estimate, with a record in consumables and guidance reaffirmed.
Technicals: The stock gave up the ~$1.31 area it traded at before August earnings and bottomed near $0.86. Monday’s move is a first reclaim of $1.
Fundamentals: EPS was -$0.27 against -$0.24 expected. A Trinity Capital term loan of up to $45 million, with $20 million drawn at close, funds growth.
Bull Case: Growing consumables, margin expansion and deep analyst upside. Bear Case: Persistent losses, debt service and a stock that fell ~78% from its high.
What to Watch:
- A hold above $0.92
- System placement updates
- Q3 results in November
Forecast: Above $1.10 targets $1.31. Below $0.92, the 52-week low at $0.86 is the line.
Why This Matters: RPID is a revenue-growth micro cap, which makes it more fundamental than most names on this list.
7. Black Titan (BTTC) | Last Close ~$0.86 (+32.8%) | Crypto-Adjacent Momentum
The Malaysia-Based Shell With a 97% Annual Loss and a 118% Single-Day Spike
Black Titan jumped 117.8% on September 21, its largest daily move of the year, on what appeared to be momentum and filing attention rather than a clear operating update. Monday brought another leg.
| Metric | Value |
|---|---|
| Last Close | ~$0.86 (per Benzinga board) |
| Previous Close | ~$0.65 (Friday, Oct 2) |
| Day’s Move | +32.8% |
| Day’s Range | ~$0.62 – $0.90 |
| 52-Week Range | Low ~$0.34; high well above $10 (sources disagree on exact figure) |
| Market Cap | ~$12M (about $9M at Friday’s price) |
| P/E / Dividend | N/A (net loss ~$2.5M, one year) / None |
| Volume vs. Average | 30.6M+ vs. 11.1M |
| YTD / Trend | Roughly -50% YTD (est.); -97.3% over 12 months |
| Analyst View | No Wall Street coverage located |
| Support 1 / 2 / 3 | $0.65 / $0.42 / $0.34 |
| Resistance 1 / 2 / 3 | $0.90 / $1.00 / $1.20 |
Catalyst & Latest News: A September 18 filing covered stablecoin and digital-payments analysis, and a convertible note was fully converted. There was an interim co-CEO change in July. We found no Monday-specific company news.
Technicals: Daily moves over 5% have occurred in 83 of the last 252 sessions. That is a speculative trading vehicle, not a trend stock.
Fundamentals: The company came from the Titan Pharmaceuticals merger and is headquartered in Petaling Jaya, Malaysia. Revenue is negligible and the digital-asset strategy remains framework-level.
Bull Case: A heavily shorted, tiny-float crypto-adjacent name can run on any stablecoin headline. Bear Case: A 97% annual drawdown, convertible-note history and no identified operating catalyst.
What to Watch:
- A hold above $0.65
- Any new financing or note filing
- Volume fade after two big sessions
Forecast: A break of $0.90 points to $1.00. Losing $0.65 likely returns to the $0.40s.
Why This Matters: BTTC is the highest-risk name here, and a reminder that volume is not validation.
8. Canaan (CAN) | Last Close $0.3328 (-4.97%) | Bitcoin-Miner Maker Bleeds
The Avalon Rig Maker 85% Below Its High, but 119% Above Its August Low
Yahoo Finance shows Canaan closed at $0.3328, down 4.97% from $0.3502, on 8.09 million shares versus a 15.93 million average.
| Metric | Value |
|---|---|
| Last Close | $0.3328 |
| Previous Close | $0.3502 (Friday, Oct 2) |
| Day’s Move | -4.97% |
| Day’s Range | $0.3230 – $0.3599 |
| 52-Week Range | $0.152 (Aug 3) – $2.22 (Oct 20, 2025) |
| Market Cap | ~$243.6M |
| P/E / Dividend | N/A (EPS -$0.45) / None |
| Volume vs. Average | 8.09M vs. 15.93M (~0.5x) |
| YTD / Trend | ~-85% from the 52-week high; +119% from the August low |
| Analyst View | No current consensus located |
| Support 1 / 2 / 3 | $0.323 / $0.30 / $0.15 |
| Resistance 1 / 2 / 3 | $0.36 / $0.38 / $0.44 |
Catalyst & Latest News: Q2 revenue of $32 million missed the $35–45 million guidance, citing weak mining-machine demand and pricing pressure. Next earnings are estimated for November 17.
Technicals: Beta is 2.64. The stock is basing in the $0.32–$0.40 range, with Monday’s low at $0.323 the line to hold.
Fundamentals: Investors are weighing whether bitcoin holdings, mining cash flow and compute-to-heat projects can offset falling equipment sales.
Bull Case: A sector rebound could revive hardware orders, and the stock has already doubled off its August low. Bear Case: Missed guidance, an EPS loss of $0.45 and sub-$1 status that risks Nasdaq bid-price scrutiny.
What to Watch:
- $0.323 support
- Monthly bitcoin-production updates
- Bitcoin price and miner sentiment
Forecast: Holding $0.323 keeps a bounce toward $0.38 alive. A break opens $0.30, then the $0.15 low.
Why This Matters: CAN is the largest market cap here and the best read on bitcoin-mining hardware demand.
9. Cognition Therapeutics (CGTX) | Last Close Roughly $0.91 | FDA Meeting October 20
A $3 Buy Rating, an Alzheimer’s Pipeline and a Date Circled on the Calendar
H.C. Wainwright reiterated Buy with a $3.00 target ahead of a Type C FDA meeting set for October 20.
| Metric | Value |
|---|---|
| Last Close | Roughly $0.91 (implied by $88M market cap; not confirmed) |
| Previous Close | Roughly $0.94 (Sep 29: $0.94) |
| Day’s Move | Not confirmed |
| Day’s Range | Not confirmed |
| 52-Week Range | $0.55 – $2.57 (as of Sept 10) |
| Market Cap | ~$88M |
| P/E / Dividend | N/A / None |
| Volume vs. Average | Not confirmed |
| YTD / Trend | Drifting near $0.90–$0.98 through September |
| Analyst View | H.C. Wainwright Buy, $3.00 target |
| Support 1 / 2 / 3 | $0.88 / $0.75 / $0.55 |
| Resistance 1 / 2 / 3 | $0.98 / $1.50 / $2.57 |
Catalyst & Latest News: Cognition announced the Division of Neurology meeting will align on endpoint analytics and statistics for a Phase 3 study of zervimesine in dementia with Lewy bodies psychosis. Patients would take 100 mg daily or placebo for nine months.
Technicals: The stock has held a narrow $0.90–$0.99 range for weeks, which makes October 20 a potential range-break event.
Fundamentals: The current ratio is about 7.0 and the Q2 net loss narrowed. A pivotal program is expected to start in mid-2027. A new composition-of-matter patent extends IP coverage.
Bull Case: FDA alignment on endpoints would de-risk Phase 3 and could re-rate the stock toward the $3 target. Bear Case: A pivotal start is still roughly nine months away, and a vague outcome could disappoint.
What to Watch:
- The October 20 meeting readout
- A hold above $0.88
- Funding plans for Phase 3
Forecast: Run-up trading into the meeting can test $0.98–$1.00. A “no alignment” headline risks $0.75.
Why This Matters: CGTX is a dated-catalyst setup, rare among penny stocks and easy to plan around.
10. Worksport (WKSP) | Last Close $0.4060 (-11.2%) | Resale Registration Overhang
Solar Truck Covers Meet a Share-Resale Filing on the Same Day
Worksport closed at $0.4060, down 11.18%, after filing a registration statement on October 5 covering resale of up to 4.8 million shares by selling stockholders. The company is not selling any shares in that filing.
| Metric | Value |
|---|---|
| Last Close | $0.4060 (after-hours $0.4118) |
| Previous Close | ~$0.457 (Friday, Oct 2) |
| Day’s Move | -11.2% |
| Day’s Range | Not confirmed |
| 52-Week Range | Not confirmed; closed above $1.00 on June 24 |
| Market Cap | Not confirmed (aggregators disagree) |
| P/E / Dividend | N/A (loss-making) / None |
| Volume vs. Average | Not confirmed |
| YTD / Trend | Fell from above $1.00 in June to ~$0.41 |
| Analyst View | No consensus located |
| Support 1 / 2 / 3 | $0.40 / $0.35 / $0.30 |
| Resistance 1 / 2 / 3 | $0.457 / $0.50 / $0.60 |
Catalyst & Latest News: The overhang is the headline. Operationally, the company reported record $2.5 million July orders, a $30 million annualized run rate, and its COR energy system is now on Amazon, per ChartMill’s news feed.
Technicals: The stock regained a $1 bid in June after a premium direct investment, then gave back most of it. It now sits back under the Nasdaq $1 threshold.
Fundamentals: Q2 operating cash use fell 58% and net loss narrowed 32%. Management targets operating cash-flow positivity within 12 months. FY2025 revenue rose 91% to about $16.2 million.
Bull Case: Rising orders, narrowing losses, product launches (SOLIS, COR) and distribution wins. Bear Case: Resale supply, a sub-$1 price and a history of capital raises.
What to Watch:
- A reclaim of $0.457
- Resale-registration effectiveness
- Monthly order updates
Forecast: Above $0.457 targets $0.50. Under $0.40, $0.35 is the next support.
Why This Matters: WKSP is the fundamental-improvement story with a technical overhang, a mismatch worth watching.
Penny Stocks Sector Snapshot: Where the Risk Sits
Biotech and medtech names (BEAT, PDSB, HUMA, CGTX, RPID) are catalyst-driven and sensitive to financing news. Crypto-linked names (CAN, BTTC) sit near lows, with CAN missing its own guidance. Quantum (QTEX) and the SCKT spike are pure momentum. A 10-year yield at 5.3% and a Fed minutes release Wednesday argue for tight risk control. For an earlier read on how small-cap rallies fade, review our July 17 penny stocks list, and for large-cap context see stocks to watch on Aug 7 and September’s top trending stocks.
Forecast for Tuesday: Expect the three Monday spikes (BEAT, SCKT, QTEX) to be volatile with fade risk. CGTX and HUMA are the “wait for the level” setups, and CAN and WKSP depend on whether support holds.
Penny Stocks At a Glance
| Ticker | Last Close | Move | Market Cap | Key Catalyst | Support | Resistance | Bias |
|---|---|---|---|---|---|---|---|
| BEAT | ~$0.65 | +50.5% | $38.2M | FDA Breakthrough Designation | $0.55 | $0.72 | Momentum, fade risk |
| SCKT | $0.93 | +31.6% | ~$7.7M | No news; earnings ~Oct 21 | $0.85 | $1.00 | Highly speculative |
| PDSB | $1.07 | +42.3% | ~$74.7M | PDS0301 focus, PIPE | $0.78 | $1.18 | Extended |
| QTEX | $1.29 | +17.3% | ~$83–90M | Quantum deal “within weeks” | $1.10 | $1.45 | Headline-driven |
| HUMA | ~$0.50 | ~-4% | ~$144.5M | Dialysis sBLA (Nov) | $0.50 | $0.64 | Watch support |
| RPID | ~$1.07 | +16.8% | ~$42M+ | Q2 beat, Q3 in Nov | $0.92 | $1.10 | Rebound attempt |
| BTTC | ~$0.86 | +32.8% | ~$12M | No identified news | $0.65 | $0.90 | Very high risk |
| CAN | $0.3328 | -4.97% | ~$243.6M | Q2 guidance miss | $0.323 | $0.36 | Base test |
| CGTX | ~$0.91 | n/a | ~$88M | FDA meeting Oct 20 | $0.88 | $0.98 | Dated catalyst |
| WKSP | $0.4060 | -11.2% | n/a | Resale filing; record orders | $0.40 | $0.457 | Overhang |
Follow TNN for daily stock market news and financial news today.
Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss, and penny stocks and micro-cap names carry elevated risk, including extreme volatility, thin liquidity, dilution and delisting risk. Stock prices, percentage moves, and market data cited reflect figures available at the time of publication and are subject to change as trading continues. Analyst price targets and ratings are third-party estimates and do not guarantee actual results. Always complete independent due diligence prior to executing equity trades.
About The Author
